Literature DB >> 31641056

ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes.

Varun Rawat1, Shaowei Wang1, Jian Sima1, Roni Bar2, Ori Liraz2, Usha Gundimeda1, Trusha Parekh1, Jamie Chan1, Jan O Johansson3, Chongren Tang4, Helena C Chui1, Michael G Harrington5, Daniel M Michaelson2, Hussein N Yassine6.   

Abstract

The APOE ε4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). ApoE protein aggregation plays a central role in AD pathology, including the accumulation of β-amyloid (Aβ). Lipid-poor ApoE4 protein is prone to aggregate and lipidating ApoE4 protects it from aggregation. The mechanisms regulating ApoE4 aggregation in vivo are surprisingly not known. ApoE lipidation is controlled by the activity of the ATP binding cassette A1 (ABCA1). ABCA1 recycling and degradation is regulated by ADP-ribosylation factor 6 (ARF6). We found that ApoE4 promoted greater expression of ARF6 compared with ApoE3, trapping ABCA1 in late-endosomes and impairing its recycling to the cell membrane. This was associated with lower ABCA1-mediated cholesterol efflux activity, a greater percentage of lipid-free ApoE particles, and lower Aβ degradation capacity. Human CSF from APOE ε4/ε4 carriers showed a lower ability to induce ABCA1-mediated cholesterol efflux activity and greater percentage of aggregated ApoE protein compared with CSF from APOE ε3/ε3 carriers. Enhancing ABCA1 activity rescued impaired Aβ degradation in ApoE4-treated cells and reduced both ApoE and ABCA1 aggregation in the hippocampus of male ApoE4-targeted replacement mice. Together, our data demonstrate that aggregated and lipid-poor ApoE4 increases ABCA1 aggregation and decreases ABCA1 cell membrane recycling. Enhancing ABCA1 activity to reduce ApoE and ABCA1 aggregation is a potential therapeutic strategy for the prevention of ApoE4 aggregation-driven pathology.SIGNIFICANCE STATEMENT ApoE protein plays a key role in the formation of amyloid plaques, a hallmark of Alzheimer's disease (AD). ApoE4 is more aggregated and hypolipidated compared with ApoE3, but whether enhancing ApoE lipidation in vivo can reverse ApoE aggregation is not known. ApoE lipidation is controlled by the activity of the ATP binding cassette A1 (ABCA1). In this study, we demonstrated that the greater propensity of lipid-poor ApoE4 to aggregate decreased ABCA1 membrane recycling and its ability to lipidate ApoE. Importantly, enhancing ABCA1 activity to lipidate ApoE reduced ApoE and ABCA1 aggregation. This work provides critical insights into the interactions among ABCA1, ApoE lipidation and aggregation, and underscores the promise of stabilizing ABCA1 activity to prevent ApoE-driven aggregation pathology.
Copyright © 2019 the authors.

Entities:  

Keywords:  ABCA1; Alzheimer's disease; ApoE; aggregation; lipids

Year:  2019        PMID: 31641056      PMCID: PMC6880458          DOI: 10.1523/JNEUROSCI.1400-19.2019

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  40 in total

1.  Impaired Autophagy in APOE4 Astrocytes.

Authors:  Shira Simonovitch; Eran Schmukler; Alina Bespalko; Tal Iram; Dan Frenkel; David M Holtzman; Eliezer Masliah; Danny M Michaelson; Ronit Pinkas-Kramarski
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Regulation of ABCA1 expression in human keratinocytes and murine epidermis.

Authors:  Yan J Jiang; Biao Lu; Peggy Kim; Peter M Elias; Kenneth R Feingold
Journal:  J Lipid Res       Date:  2006-07-06       Impact factor: 5.922

3.  Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis.

Authors:  P M Sullivan; H Mezdour; Y Aratani; C Knouff; J Najib; R L Reddick; S H Quarfordt; N Maeda
Journal:  J Biol Chem       Date:  1997-07-18       Impact factor: 5.157

4.  Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease.

Authors:  Liv Tybjærg Nordestgaard; Anne Tybjærg-Hansen; Børge G Nordestgaard; Ruth Frikke-Schmidt
Journal:  Alzheimers Dement       Date:  2015-06-13       Impact factor: 21.566

Review 5.  Formation and function of apolipoprotein E-containing lipoproteins in the nervous system.

Authors:  Jean E Vance; Hideki Hayashi
Journal:  Biochim Biophys Acta       Date:  2010-02-17

6.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

Authors:  A M Cataldo; C M Peterhoff; J C Troncoso; T Gomez-Isla; B T Hyman; R A Nixon
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

7.  ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE.

Authors:  Suzanne E Wahrle; Hong Jiang; Maia Parsadanian; Justin Legleiter; Xianlin Han; John D Fryer; Tomasz Kowalewski; David M Holtzman
Journal:  J Biol Chem       Date:  2004-07-21       Impact factor: 5.157

8.  ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation.

Authors:  Rui Lu; Reijiro Arakawa; Chisato Ito-Osumi; Noriyuki Iwamoto; Shinji Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

9.  Apolipoprotein E4 genotype compromises brain exosome production.

Authors:  Katherine Y Peng; Rocío Pérez-González; Melissa J Alldred; Chris N Goulbourne; Jose Morales-Corraliza; Mariko Saito; Mitsuo Saito; Stephen D Ginsberg; Paul M Mathews; Efrat Levy
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

10.  Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer's disease.

Authors:  Xunde Xian; Theresa Pohlkamp; Murat S Durakoglugil; Connie H Wong; Jürgen K Beck; Courtney Lane-Donovan; Florian Plattner; Joachim Herz
Journal:  Elife       Date:  2018-10-30       Impact factor: 8.140

View more
  29 in total

Review 1.  Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk.

Authors:  Sreedevi Raman; Nicholas Brookhouser; David A Brafman
Journal:  Neurobiol Dis       Date:  2020-02-05       Impact factor: 5.996

2.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

3.  Inflammatory Pathways Are Impaired in Alzheimer Disease and Differentially Associated With Apolipoprotein E Status.

Authors:  Courtney M Kloske; Adam J Dugan; Erica M Weekman; Zachary Winder; Ela Patel; Peter T Nelson; David W Fardo; Donna M Wilcock
Journal:  J Neuropathol Exp Neurol       Date:  2021-10-26       Impact factor: 3.148

Review 4.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

5.  NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load.

Authors:  Theresa Pohlkamp; Xunde Xian; Connie H Wong; Murat S Durakoglugil; Gordon Chandler Werthmann; Takaomi C Saido; Bret M Evers; Charles L White; Jade Connor; Robert E Hammer; Joachim Herz
Journal:  Elife       Date:  2021-10-07       Impact factor: 8.713

6.  APOE alters glucose flux through central carbon pathways in astrocytes.

Authors:  Holden C Williams; Brandon C Farmer; Margaret A Piron; Adeline E Walsh; Ronald C Bruntz; Matthew S Gentry; Ramon C Sun; Lance A Johnson
Journal:  Neurobiol Dis       Date:  2020-01-11       Impact factor: 5.996

7.  Precision Nutrition for Alzheimer's Prevention in ApoE4 Carriers.

Authors:  Nicholas G Norwitz; Nabeel Saif; Ingrid Estrada Ariza; Richard S Isaacson
Journal:  Nutrients       Date:  2021-04-19       Impact factor: 5.717

Review 8.  APOE Alleles and Diet in Brain Aging and Alzheimer's Disease.

Authors:  Hussein N Yassine; Caleb E Finch
Journal:  Front Aging Neurosci       Date:  2020-06-10       Impact factor: 5.750

9.  Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes.

Authors:  Manel Ben Aissa; Cutler T Lewandowski; Kiira M Ratia; Sue H Lee; Brian T Layden; Mary Jo LaDu; Gregory R J Thatcher
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-05

Review 10.  Cholesterol and Alzheimer's Disease; From Risk Genes to Pathological Effects.

Authors:  Femke M Feringa; Rik van der Kant
Journal:  Front Aging Neurosci       Date:  2021-06-24       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.